Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $1.53, $0.15 better than the analyst estimate of $1.38. Revenue for the quarter came in at $585.3 million versus the consensus estimate of $567.79 million.

GUIDANCE:

Charles River Laboratories sees FY2018 EPS of $5.87-$5.97, versus the consensus of $5.92.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.